EP2405755A4 - Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires - Google Patents

Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires

Info

Publication number
EP2405755A4
EP2405755A4 EP10751135A EP10751135A EP2405755A4 EP 2405755 A4 EP2405755 A4 EP 2405755A4 EP 10751135 A EP10751135 A EP 10751135A EP 10751135 A EP10751135 A EP 10751135A EP 2405755 A4 EP2405755 A4 EP 2405755A4
Authority
EP
European Patent Office
Prior art keywords
metabolic
compositions
treatment
methods
cardiovascular disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10751135A
Other languages
German (de)
English (en)
Other versions
EP2405755A1 (fr
Inventor
Arnold Stan Lippa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XINTRIA PHARMACEUTICAL CORP Inc
Original Assignee
XINTRIA PHARMACEUTICAL CORP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XINTRIA PHARMACEUTICAL CORP Inc filed Critical XINTRIA PHARMACEUTICAL CORP Inc
Publication of EP2405755A1 publication Critical patent/EP2405755A1/fr
Publication of EP2405755A4 publication Critical patent/EP2405755A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP10751135A 2009-03-11 2010-03-11 Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires Withdrawn EP2405755A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15942309P 2009-03-11 2009-03-11
US15942909P 2009-03-11 2009-03-11
US15942709P 2009-03-11 2009-03-11
PCT/US2010/000750 WO2010104595A1 (fr) 2009-03-11 2010-03-11 Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires

Publications (2)

Publication Number Publication Date
EP2405755A1 EP2405755A1 (fr) 2012-01-18
EP2405755A4 true EP2405755A4 (fr) 2012-11-28

Family

ID=42728640

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10751135A Withdrawn EP2405755A4 (fr) 2009-03-11 2010-03-11 Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires

Country Status (2)

Country Link
EP (1) EP2405755A4 (fr)
WO (1) WO2010104595A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102735782A (zh) * 2011-04-12 2012-10-17 中国科学院长春应用化学研究所 一种筛选α-葡萄糖苷酶抑制剂的方法
WO2013016742A1 (fr) * 2011-07-22 2013-01-31 Smith Conrad Anton Composition utilisable dans le cadre d'un traitement contre l'obésité
US8420131B2 (en) 2011-07-25 2013-04-16 Conrad Anton Smith Composition for obesity treatment
CN103421003A (zh) * 2012-05-23 2013-12-04 中国医学科学院药物研究所 具有调脂降血糖作用的黄连碱衍生物
CN103919774A (zh) * 2013-12-20 2014-07-16 中国药科大学 去亚甲基小檗碱在制备降血脂药物中的应用
WO2015183909A1 (fr) 2014-05-27 2015-12-03 Case Western Reserve University Système et procédé de détection de lésion neurologique
WO2015185158A1 (fr) * 2014-06-06 2015-12-10 AYDIN, Ahmet Nurettin Composition et dispositif pour le traitement du diabète
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
US12551467B2 (en) 2014-12-05 2026-02-17 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
EP3226859B1 (fr) * 2014-12-05 2025-03-26 Case Western Reserve University Inhibiteurs de l'akr1a1 utilisés pour réduire le cholestérol et moduler la s-nitrosylation
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
US20160302451A1 (en) 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CN105560232B (zh) * 2015-12-25 2017-11-28 东北制药集团沈阳第一制药有限公司 一种小檗碱与辛伐他汀的药物组合物及其用途
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
AU2016406709C1 (en) * 2016-05-10 2023-04-27 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
WO2018144911A1 (fr) 2017-02-02 2018-08-09 Golo Llc Formulations amaigrissantes et procédés d'utilisation
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN111356764B (zh) 2017-09-25 2024-05-24 卡斯西部储备大学 降低血清胆固醇和pcsk9的组合物和方法
CN107722000A (zh) * 2017-11-03 2018-02-23 中国药科大学 9位－取代的小檗碱衍生物的制备及其医药用途
CN108101902B (zh) * 2017-12-27 2020-05-15 四川大学 高b环小檗碱和巴马亭衍生物的合成及作为降血糖的用途
US11931339B2 (en) 2018-06-25 2024-03-19 Case Western Reserve University Compositions and methods for treating tissue injury
AU2019344066B2 (en) 2018-09-21 2025-05-29 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
US12391703B2 (en) 2019-09-23 2025-08-19 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
US11697807B2 (en) 2019-09-30 2023-07-11 Case Western Reserve University Electrochemical biosensor
US20220387403A1 (en) * 2019-10-01 2022-12-08 Jingwen Liu Compounds, compositions and methods for treating nash, nafld, and obesity
WO2021142815A1 (fr) * 2020-01-18 2021-07-22 中国医学科学院药物研究所 Berbérine et coptisine, ou métabolites actifs associés et application de sels associés dans un médicament destiné à la prévention et/ou au traitement d'une néphropathie à l'acide urique
CN112138007B (zh) * 2020-09-23 2021-12-28 广州中医药大学(广州中医药研究院) 氧化小檗碱在制备代谢性疾病药物中的应用及包含氧化小檗碱的药物组合物
CN114163433B (zh) * 2021-12-21 2022-11-25 哈尔滨医科大学 一种小檗碱衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003970A1 (fr) * 1982-05-14 1983-11-24 Maroko Peter R Composes, compositions et procede de traitement permettant d'ameliorer la circulation
WO2001095908A1 (fr) * 2000-06-15 2001-12-20 Hanwha Chemical Corporation Derives de la protoberberine inhibant l'activite de la proteine kinase activee par mitogene
WO2004032924A1 (fr) * 2002-10-10 2004-04-22 Jiandong Jiang Emploi de berberine en tant que sensibilisant insulinique
WO2006029577A1 (fr) * 2004-09-17 2006-03-23 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Methodes et compositions de traitement de l'hyperlipidemie
WO2007113748A1 (fr) * 2006-03-30 2007-10-11 Rottapharm S.P.A. Formulation orale présentant des effets cardiovasculaires bénéfiques comprenant de la berbérine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
CN101153039B (zh) * 2006-09-30 2010-12-01 中国科学院上海药物研究所 13，13a-二氢小檗碱衍生物及其药物组合物和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003970A1 (fr) * 1982-05-14 1983-11-24 Maroko Peter R Composes, compositions et procede de traitement permettant d'ameliorer la circulation
WO2001095908A1 (fr) * 2000-06-15 2001-12-20 Hanwha Chemical Corporation Derives de la protoberberine inhibant l'activite de la proteine kinase activee par mitogene
WO2004032924A1 (fr) * 2002-10-10 2004-04-22 Jiandong Jiang Emploi de berberine en tant que sensibilisant insulinique
WO2006029577A1 (fr) * 2004-09-17 2006-03-23 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Methodes et compositions de traitement de l'hyperlipidemie
WO2007113748A1 (fr) * 2006-03-30 2007-10-11 Rottapharm S.P.A. Formulation orale présentant des effets cardiovasculaires bénéfiques comprenant de la berbérine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010104595A1 *

Also Published As

Publication number Publication date
EP2405755A1 (fr) 2012-01-18
WO2010104595A1 (fr) 2010-09-16

Similar Documents

Publication Publication Date Title
EP2405755A4 (fr) Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires
EP2552433A4 (fr) Compositions et procédés pour le traitement de troubles somatosensoriels
WO2011049960A9 (fr) Compositions et méthodes pour le traitement des troubles nasosinusiens
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
IL215592A0 (en) Compositions and methods for the treatment of inflammation
ZA201007127B (en) Carboxamide compounds for the treatment of metabolic disorders
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL218212A0 (en) Therapeutic methods and compositions
EP2429584A4 (fr) Procédés et compositions de traitement
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PL2300614T3 (pl) Sposoby i kompozycje do leczenia zaburzeń mitochondrialnych
ZA201201290B (en) Methods and compositions for treatment of pulmonary fibrotic disorders
GB0904287D0 (en) Compounds for the treatment of metabolic disorders
ZA201107449B (en) Compounds for the treatment of metabolic disorders
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
ZA201107445B (en) Compound for the treatment of metabolic disorders
WO2012021287A9 (fr) Procédés pour le traitement et la prévention de maladies métaboliques
IL212353A0 (en) Compositions and methods for treatment of kidney disorders
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2405747A4 (fr) Compositions et méthodes de traitement et prévention de maladies cardiovasculaires
PL2328402T3 (pl) Sposoby i kompozycje do wydłużenia okresu przechowywania owoców
HU0900231D0 (en) Compositions for the treatment of allergic disorders
EP2461870A4 (fr) Compositions thérapeutiques et procédés associés
EP2480099A4 (fr) Compositions et procédés de prévention et de traitement de maladies métaboliques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121025

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20121019BHEP

Ipc: A61K 31/4741 20060101AFI20121019BHEP

Ipc: A61P 3/04 20060101ALI20121019BHEP

Ipc: A61P 3/06 20060101ALI20121019BHEP

Ipc: A61K 45/06 20060101ALI20121019BHEP

Ipc: A61P 3/10 20060101ALI20121019BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130524